• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作为政治参与者的制药行业。

The pharmaceutical industry as a political player.

作者信息

Abraham John

机构信息

Centre for Research in Health and Medicine, University of Sussex, BN1 9SN, Brighton, UK.

出版信息

Lancet. 2002 Nov 9;360(9344):1498-502. doi: 10.1016/S0140-6736(02)11477-2.

DOI:10.1016/S0140-6736(02)11477-2
PMID:12433532
Abstract

The pharmaceutical industry has produced many drugs that have benefited man. Political frameworks designed to govern the industry must maintain these benefits. However, regulation needs to be sufficiently robust to protect public health from drugs that are unsafe, ineffective, or unnecessary. The extent of industry influence over drug regulation, at the expense of other interested parties, suggests that the current system could be more robust. The many ways in which the pharmaceutical industry can influence governments and regulatory agencies are discussed, and methods by which this influence can be curbed are suggested.

摘要

制药行业已生产出许多造福人类的药物。旨在管理该行业的政治框架必须维持这些益处。然而,监管必须足够有力,以保护公众健康免受不安全、无效或不必要药物的侵害。制药行业对药品监管的影响程度,是以牺牲其他利益相关方为代价的,这表明当前体系可能需要更强有力。本文讨论了制药行业影响政府和监管机构的多种方式,并提出了抑制这种影响的方法。

相似文献

1
The pharmaceutical industry as a political player.作为政治参与者的制药行业。
Lancet. 2002 Nov 9;360(9344):1498-502. doi: 10.1016/S0140-6736(02)11477-2.
2
EU directive on clinical trials penalizes small sponsors.欧盟关于临床试验的指令对小型赞助商进行处罚。
Nat Biotechnol. 2003 Aug;21(8):838. doi: 10.1038/nbt0803-838.
3
Evaluation of similar biotherapeutic products: scientific and regulatory challenges.相似生物治疗产品的评估:科学与监管挑战
Biologicals. 2011 Sep;39(5):249. doi: 10.1016/j.biologicals.2011.09.004. Epub 2011 Sep 16.
4
Policy making on data exclusivity in the European Union: from industrial interests to legal realities.欧盟数据独占政策制定:从产业利益到法律现实。
J Health Polit Policy Law. 2009 Dec;34(6):979-1010. doi: 10.1215/03616878-2009-033.
5
Pharmaceutical regulation in Greece at the crossroad of change: economic, political and constitutional considerations for a new regulatory paradigm.处于变革十字路口的希腊药品监管:新监管范式的经济、政治和宪法考量
Health Policy. 2007 Jun;82(1):116-29. doi: 10.1016/j.healthpol.2006.09.003. Epub 2006 Oct 17.
6
The science and politics of medicines control.药品管制的科学与政策
Drug Saf. 2003;26(3):135-43. doi: 10.2165/00002018-200326030-00001.
7
Australian government loosens its grip on the pharmaceutical industry.澳大利亚政府放松了对制药行业的管控。
Lancet. 2001 Feb 10;357(9254):453. doi: 10.1016/S0140-6736(05)71269-1.
8
A generic problem.一个一般性问题。
Nat Clin Pract Gastroenterol Hepatol. 2006 Dec;3(12):649. doi: 10.1038/ncpgasthep0659.
9
[Fake drugs, what are we talking about? Counterfeit drugs, informal market, quality of pharmaceutical… Thought from an anthropological study led in Benin].[假药,我们在谈论什么?假冒药品、非正式市场、药品质量……来自在贝宁开展的一项人类学研究的思考]
Bull Soc Pathol Exot. 2014 May;107(2):121-6. doi: 10.1007/s13149-014-0354-9. Epub 2014 Mar 17.
10
Financial conflicts of interest in physicians' relationships with the pharmaceutical industry--self-regulation in the shadow of federal prosecution.医生与制药行业关系中的经济利益冲突——在联邦起诉阴影下的自我监管。
N Engl J Med. 2004 Oct 28;351(18):1891-900. doi: 10.1056/NEJMlim042229.

引用本文的文献

1
The Political Economy of the World Health Organization Model Lists of Essential Medicines.世界卫生组织基本药物示范清单的政治经济学
Milbank Q. 2025 Mar;103(1):52-99. doi: 10.1111/1468-0009.70001. Epub 2025 Feb 27.
2
When Public Health Goes Wrong: Toward a New Concept of Public Health Error.当公共卫生出错时:迈向新的公共卫生错误概念。
J Law Med Ethics. 2023;51(2):385-402. doi: 10.1017/jme.2023.67. Epub 2023 Sep 1.
3
COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities.
为年轻人接种 COVID-19 疫苗加强针:对大学强制接种政策的风险收益评估和伦理分析。
J Med Ethics. 2024 Jan 23;50(2):126-138. doi: 10.1136/jme-2022-108449.
4
A Qualitative Study of Stakeholders' Views on Pharmacovigilance System, Policy, and Coordination in Pakistan.关于巴基斯坦利益相关者对药物警戒系统、政策及协调的观点的定性研究
Front Pharmacol. 2022 Jun 9;13:891954. doi: 10.3389/fphar.2022.891954. eCollection 2022.
5
Public health and the legal regulation of the pharmaceutical industry in Algeria.阿尔及利亚的公共卫生与药品行业的法律监管
Pan Afr Med J. 2022 Feb 1;41:86. doi: 10.11604/pamj.2022.41.86.31524. eCollection 2022.
6
A hidden web of policy influence: The pharmaceutical industry's engagement with UK's All-Party Parliamentary Groups.政策影响的隐秘网络:制药业与英国各党派议会团体的互动。
PLoS One. 2021 Jun 24;16(6):e0252551. doi: 10.1371/journal.pone.0252551. eCollection 2021.
7
A holistic approach to the patients/ Families with inborn errors of metabolism.对先天性代谢缺陷患者/家庭采取整体方法。
J Mother Child. 2020 Oct 2;24(2):65-72. doi: 10.34763/jmotherandchild.20202402si.2004.000010.
8
Regulatory Capture in Pharmaceutical Policy Making: The Case of National Medicine Agencies Related to the EU Falsified Medicines Directive.药品政策制定中的监管俘获:与欧盟假药指令相关的国家药品机构案例
Pharmaceut Med. 2019 Jun;33(3):199-207. doi: 10.1007/s40290-019-00277-0.
9
Power asymmetries in global governance for health: a conceptual framework for analyzing the political-economic determinants of health inequities.全球卫生治理中的权力不对称:分析健康不平等的政治经济决定因素的概念框架。
Global Health. 2019 Nov 28;15(Suppl 1):70. doi: 10.1186/s12992-019-0516-4.
10
The intersections of industry with the health research enterprise.产业与健康研究企业的交集。
Health Res Policy Syst. 2019 May 29;17(1):53. doi: 10.1186/s12961-019-0457-7.